Yield10 Bioscience Files Request for Regulatory Status Review under USDA-APHIS’s SECURE Rule Covering Elite Camelina Designed to Produce the EPA Component of Omega-3 Oil
26 Juillet 2023 - 2:40PM
Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the
“Company”), an agricultural bioscience company, today announced
that the Company recently filed a request for a Regulatory Status
Review (RSR) with USDA-APHIS Biotechnology Regulatory Services
(BRS) under the SECURE Rule for proprietary elite Camelina
varieties containing genes enabling the plant to produce the
eicosapentaenoic acid (“EPA”) component of omega-3 oil. In spring
2023, Yield10 planted omega-3 (EPA) Camelina at acre-scale in the
U.S. to begin the ramp up of seed inventory for future planting as
well as to produce oil for use in business development
activities.
“We believe that Camelina represents an ideal platform for the
sustainable, land-based production of high value, omega-3 oils
targeting the significant market opportunity in animal feed and
human nutrition,” said Kristi Snell, Ph.D., Chief Science Officer
of Yield10 Bioscience. “This RSR filing is a key milestone for our
team as we execute our strategy to develop Camelina for large-scale
production of omega-3 oils. As we await the response to our RSR
filing, we remain focused on conducting seed scale-up activities to
generate seed inventory for regulatory activities and future grower
contracts.”
A photo accompanying this announcement is
available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/14711a8c-b94b-441d-9b99-be4bd004e7a5
Camelina containing the omega-3 EPA trait growing
at acre-scale in the U.S. in spring 2023.
In late 2020, Yield10 signed a collaboration agreement with
UK-based Rothamsted Research to support the development of omega-3
oils in Camelina. In addition, Yield10 signed an exclusive option
to sign a global, exclusive or non-exclusive license agreement to
the Rothamsted omega-3 technology. Yield10 has prioritized the
deployment of the EPA component of omega-3 in Camelina as the
initial oil profile for commercialization. Yield10 also plans to
produce the EPA component of omega-3 co-deployed in Camelina with
its advanced technology for a robust trait package including
herbicide tolerance. The Company plans to follow this with the
development of advanced EPA plus docosahexaenoic acid (“DHA”)
producing Camelina varieties.
About the EPA component of Omega-3 oil EPA is a
polyunsaturated fat (PUFA) that is primarily supplied in the human
diet by the consumption of oily fish such as salmon, anchovies, and
mackerel. Fish obtain EPA through the consumption of algae.
Clinical studies have shown that EPA is beneficial to humans as it
lowers triglycerides and reduces low-density lipoprotein (LDL
cholesterol) in the blood with beneficial cardiovascular effects.
Using Camelina to produce EPA may represent a way to produce this
beneficial ingredient without relying on the harvest of ocean fish.
Several commercial products containing EPA fatty acids are
available on the market including pharmaceuticals, nutritional
supplements, and animal feed.
About the SECURE Rule
The SECURE Rule was published on May 18, 2020 and represents the
first comprehensive revision of APHIS’ biotechnology regulations
since 1987. The revisions enable APHIS to regulate organisms
developed using genetic engineering for plant pest risk with
greater precision and reduces the regulatory burden for developers
of organisms that are unlikely to pose plant pest risks. Once a
specific plant developed through genetic engineering is found not
to require regulation, new varieties of the plant containing the
same genetic modification would similarly not be regulated.
Camelina plants containing omega-3 traits are subject to regulation
by the U.S. Food and Drug Administration.
About Yield10 Bioscience
Yield10 Bioscience, Inc. is an agricultural bioscience company
that is using its differentiated trait gene discovery platform, the
“Trait Factory”, to develop improved Camelina varieties for the
production of proprietary seed products, and to discover high value
genetic traits for the agriculture and food industries. Our goals
are to efficiently establish a high value seed products business
based on developing superior varieties of Camelina for the
production of feedstock oils, PHA bioplastics and omega-3 (EPA,
DHA) oils, and to license our yield traits to major seed companies
for commercialization in major row crops, including corn, soybean
and canola. Yield10 is headquartered in Woburn, MA and has a
Canadian subsidiary, Yield10 Oilseeds Inc., located in Saskatoon,
Canada.
For more information about the company, please visit
www.yield10bio.com, or follow the Company on Twitter, Facebook and
LinkedIn.
(YTEN-G)
Safe Harbor for
Forward-Looking Statements
This press release contains forward-looking statements which are
made pursuant to the safe harbor provisions of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. The forward-looking
statements in this release do not constitute guarantees of future
performance. Investors are cautioned that statements in this press
release which are not strictly historical, including, without
limitation, the potential for Camelina to become an ideal platform
for the sustainable, land-based production of high value omega-3
oil, the outcome of Yield10’s RSR filing, and future plans for the
development of the EPA component of omega-3 in
Camelina, constitute forward-looking statements.
Such forward-looking statements are subject to a number of risks
and uncertainties that could cause actual results to differ
materially from those anticipated, including the risks and
uncertainties detailed in Yield10 Bioscience’s filings with the
Securities and Exchange Commission. Yield10 assumes no obligation
to update any forward-looking information contained in this press
release or with respect to the matters described herein.
Contacts: Yield10 Bioscience:Lynne H. Brum,
(617) 682-4693, LBrum@yield10bio.com
Investor Relations: Bret Shapiro, (561) 479-8566,
brets@coreir.comManaging Director, CORE IR
Media Inquiries: Eric Fischgrund, eric@fischtankpr.com FischTank
PR
Yield10 Bioscience (NASDAQ:YTEN)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Yield10 Bioscience (NASDAQ:YTEN)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024